Kestrel SDS

Download as pdf or txt
Download as pdf or txt
You are on page 1of 11

SAFETY DATA SHEET

KESTREL 1/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE


COMPANY/UNDERTAKING

1.1 Product identifier


Trade name KESTREL
Product code (UVP) 79044224, 86234785

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use Fungicide
EPA-Nr. HSR101293

1.3 Details of the supplier of the safety data sheet


Supplier Bayer New Zealand Limited
CropScience Division
B:HIVE Building
74 Taharoto Rd
Smales Farm
Takapuna
Auckland, 0622
New Zealand
Telephone 0800 428 246

Telefax (09) 441 8645

1.4 Emergency telephone no.


Emergency Number 0800 734 607 (24hr)
Global Incident Response +1 (760) 476-3964 (Company 3E for Bayer AG, Crop Science Division)
Hotline (24h)

SECTION 2: HAZARDS IDENTIFICATION

2.1 Classification of the substance or mixture


Classified as hazardous according to the criteria in the Hazardous Substances (Minimum
Degrees of Hazard) Notice 2020 as amended
Skin Irrit. 2
H315 Causes skin irritation.
Eye Irrit. 2
H319 Causes serious eye irritation.
Repr. 2
H361 Suspected of damaging fertility or the unborn child.
SAFETY DATA SHEET

KESTREL 2/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

STOT RE 2
H372 Causes damage to organs through prolonged or repeated exposure if
swallowed.
Aquatic Chronic 2
H410 Very toxic to aquatic life with long lasting effects.
H433 Harmf ul to terrestrial vertebrates.
2.2 Label elements
Labelling in accordance with the Hazardous Substances (Safety Data Sheets) Notice 2020 as
amended
Hazard label f or supply/use required.

Signal word: Warning


Hazard statements
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H361 Suspected of damaging fertility or the unborn child.
H372 Causes damage to organs through prolonged or repeated exposure if swallowed.
H410 Very toxic to aquatic life with long lasting effects.
H433 Harmf ul to terrestrial vertebrates.
Precautionary statements
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P301 + P312 IF SWALLOWED: Call a POISON CENTER/doctor/physician if you feel unwell.
P304 + P312 IF INHALED: Call a POISON CENTER/doctor/physician if you feel unwell.
P391 Collect spillage.
P410 Protect from sunlight.
P501 Dispose of contents/container in accordance with local regulation.
2.3 Other hazards
No additional hazards known beside those mentioned.

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.2 Mixtures
Chemical nature
Emulsifiable concentrate (EC)
Prothioconazole/Tebuconazole 160:80 g/l
Hazardous components
Chemical name CAS-No. Conc. [%]
Tebuconazole 107534-96-3 8.1
SAFETY DATA SHEET

KESTREL 3/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

Prothioconazole 178928-70-6 16.2


N,N-Dimethyl decanamide 14433-76-2 > 20

SECTION 4: FIRST AID MEASURES

4.1 Description of first aid measures

General advice Move out of dangerous area. Place and transport victim in stable
position (lying sideways). Remove contaminated clothing immediately
and dispose of safely.
Inhalation Move to fresh air. Keep patient warm and at rest. Call a physician or
poison control center immediately.
Skin contact Wash off thoroughly with plenty of soap and water, if available with
polyethyleneglycol 400, subsequently rinse with water. Call a physician
or poison control center immediately.
Eye contact Rinse immediately with plenty of water, also under the eyelids, for at
least 15 minutes. Remove contact lenses, if present, after the first 5
minutes, then continue rinsing eye. Call a physician or poison control
center immediately.
Ingestion Do NOT induce vomiting. Call a physician or poison control center
immediately. Rinse mouth.

4.2 Most important symptoms and effects, both acute and delayed

Symptoms No symptoms known or expected.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment Treat symptomatically. Gastric lavage is not normally required.


However, if a significant amount (more than a mouthful) has been
ingested, administer activated charcoal and sodium sulphate. There is
no specific antidote.
Contact the National Poisons and Hazardous Chemicals Inf ormation center in Dunedin, PO Box 913,
Dunedin. Phone 0800 POISON (0800 764 766).

SECTION 5: FIREFIGHTING MEASURES

5.1 Extinguishing media


Suitable Use water spray, alcohol-resistant foam, dry chemical or carbon
dioxide.
Unsuitable High volume water jet
SAFETY DATA SHEET

KESTREL 4/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

5.2 Special hazards arising In the event of fire the following may be released:, Hydrogen chloride
from the substance or (HCl), Nitrogen oxides (NOx), Hydrogen cyanide (hydrocyanic acid),
mixture Carbon monoxide (CO), Sulphur oxides
5.3 Advice for firefighters
Special protective In the event of fire and/or explosion do not breathe fumes. In the event
equipment for firefighters of fire, wear self-contained breathing apparatus.
Further information Contain the spread of the fire-fighting media. Do not allow run-off from
f ire f ighting to enter drains or water courses.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures


Precautions Avoid contact with spilled product or contaminated surfaces. Use
personal protective equipment.

6.2 Environmental Do not allow to get into surface water, drains and ground water.
precautions
6.3 Methods and materials for containment and cleaning up
Methods for cleaning up Soak up with inert absorbent material (e.g. sand, silica gel, acid
binder, universal binder, sawdust). Clean contaminated floors and
objects thoroughly, observing environmental regulations. Keep in
suitable, closed containers for disposal.

6.4 Reference to other Inf ormation regarding safe handling, see section 7.
sections Inf ormation regarding personal protective equipment, see section 8.
Inf ormation regarding waste disposal, see section 13.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling


Advice on safe handling Use only in area provided with appropriate exhaust ventilation.
Advice on protection Take measures to prevent the build up of electrostatic charge. Keep
against fire and explosion away f rom heat and sources of ignition.
Hygiene measures Avoid contact with skin, eyes and clothing. Keep working clothes
separately. Wash hands before breaks and immediately after handling
the product. Remove soiled clothing immediately and clean thoroughly
bef ore using again. Garments that cannot be cleaned must be
destroyed (burnt).
7.2 Conditions for safe storage, including any incompatibilities
Requirements for storage Keep containers tightly closed in a dry, cool and well-ventilated place.
areas and containers Store in original container. Store in a place accessible by authorized
persons only.
Advice on common storage Keep away f rom food, drink and animal feedingstuffs.
Suitable materials HDPE (high density polyethylene)
SAFETY DATA SHEET

KESTREL 5/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

7.3 Specific end use(s) Ref er to the label and/or leaflet.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 Control parameters


Components CAS-No. Control parameters Update Basis
Tebuconazole 107534-96-3 0.2 mg/m3 OES BCS*
(SK-ABS)
Prothioconazole 178928-70-6 1.4 mg/m3 OES BCS*
(SK-ABS)
*OES BCS: Internal Bayer AG, Crop Science Division "Occupational Exposure Standard"
8.2 Exposure controls
Personal protective equipment
In normal use and handling conditions please refer to the label and/or leaflet. In all other cases the
f ollowing recommendations would apply.
Respiratory protection Wear respirator with an organic vapours and gas filter mask
(protection factor 10) conforming to EN140 type A or equivalent.
Respiratory protection should only be used to control residual risk of
short duration activities, when all reasonably practicable steps have
been taken to reduce exposure at source e.g. containment and/or
local extract ventilation. Always follow respirator manufacturer's
instructions regarding wearing and maintenance.

Hand protection Please observe the instructions regarding permeability and


breakthrough time which are provided by the supplier of the gloves.
Also take into consideration the specific local conditions under which
the product is used, such as the danger of cuts, abrasion, and the
contact time.
Wash gloves when contaminated. Dispose of when contaminated
inside, when perforated or when contamination on the outside cannot
be removed. Wash hands frequently and always before eating,
drinking, smoking or using the toilet.
Material Nitrile rubber
Rate of permeability > 480 min
Glove thickness > 0.4 mm
Protective index Class 6
Directive Protective gloves complying with EN
374.
Eye protection Wear goggles (conforming to EN166, Field of Use = 5 or equivalent).
Skin and body protection Wear standard coveralls and Category 3 Type 6 suit.
Wear two layers of clothing wherever possible. Polyester/cotton or
cotton overalls should be worn under chemical protection suit and
should be professionally laundered frequently.
If chemical protection suit is splashed, sprayed or significantly
contaminated, decontaminate as far as possible, then carefully
remove and dispose of as advised by manufacturer.
SAFETY DATA SHEET

KESTREL 6/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Form Liquid, clear to slightly turbid


Colour tan
Odour characteristic
Odour Threshold No data available
pH 4.5 - 6.5 (1 %) (23 °C) (deionized water)
Melting point/range No data available
Boiling Point No data available
Flash point > 100 °C
Flammability No data available
Auto-ignition temperature No data available

Minimum ignition energy No data available


Self-accelarating No data available
decomposition temperature
(SADT)
Upper explosion limit No data available
Lower explosion limit No data available
Vapour pressure No data available
Evaporation rate No data available
Relative vapour density No data available
Relative density No data available
Density ca. 0.99 g/cm³ (20 °C)

Water solubility No data available

Partition coefficient: n- Prothioconazole: log Pow: 3.82 (20 °C) (pH 7)


octanol/water
Tebuconazole: log Pow: 3.7

Viscosity, dynamic No data available


Viscosity, kinematic No data available
Oxidizing properties No data available
Explosivity No data available
9.2 Other information Further saf ety related physical-chemical data are not known.
SAFETY DATA SHEET

KESTREL 7/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

SECTION 10: STABILITY AND REACTIVITY

10.1 Reactivity Stable under normal conditions.


10.2 Chemical stability Stable under recommended storage conditions.

10.3 Possibility of No hazardous reactions when stored and handled according to


hazardous reactions prescribed instructions.

10.4 Conditions to avoid Extremes of temperature and direct sunlight.

10.5 Incompatible materials Store only in the original container.

10.6 Hazardous No decomposition products expected under normal conditions of use.


decomposition products

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 Information on toxicological effects


Acute oral toxicity LD50 cut-off (Rat) 5,000 mg/kg
Test conducted with a similar formulation.
Acute inhalation toxicity LC50 (Rat) > 5.003 mg/l
Test conducted with a similar formulation.
Acute dermal toxicity LD50 (Rat) > 4,000 mg/kg
Test conducted with a similar formulation.
Skin corrosion/irritation Irritating to skin. (Rabbit)
Test conducted with a similar formulation.
Serious eye damage/eye Irritating to eyes. (Rabbit)
irritation Test conducted with a similar formulation.
Respiratory or skin Skin: Non-sensitizing. (Guinea pig)
sensitisation OECD Test Guideline 406
Test conducted with a similar formulation.
Assessment STOT Specific target organ toxicity – single exposure
Prothioconazole: Based on available data, the classification criteria are not met.
Tebuconazole: Based on available data, the classification criteria are not met.
Assessment STOT Specific target organ toxicity – repeated exposure
Prothioconazole did not cause specific target organ toxicity in experimental animal studies.
Tebuconazole did not cause specific target organ toxicity in experimental animal studies.
Assessment mutagenicity
Prothioconazole was not mutagenic or genotoxic based on the overall weight of evidence in a battery of
in vitro and in vivo tests.
Tebuconazole was not mutagenic or genotoxic in a battery of in vitro and in vivo tests.
Assessment carcinogenicity
SAFETY DATA SHEET

KESTREL 8/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

Prothioconazole was not carcinogenic in lifetime feeding studies in rats and mice.
Tebuconazole caused at high dose levels an increased incidence of tumours in mice in the following
organ(s): Liver. The mechanism of tumour formation is not considered to be relevant to man.
Assessment toxicity to reproduction
Prothioconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also
toxic to the parent animals. The reproduction toxicity seen with Prothioconazole is related to parental
toxicity.
Tebuconazole caused reproduction toxicity in a two-generation study in rats only at dose levels also
toxic to the parent animals. The reproduction toxicity seen with Tebuconazole is related to parental
toxicity.
Assessment developmental toxicity
Prothioconazole caused developmental toxicity only at dose levels toxic to the dams. The developmental
ef f ects seen with Prothioconazole are related to maternal toxicity.
Tebuconazole caused developmental toxicity only at dose levels toxic to the dams. Tebuconazole
caused an increased incidence of post implantation losses, an increased incidence of non-specific
malf ormations.
Aspiration hazard
Based on available data, the classification criteria are not met.
Further information
Irritating to respiratory system.
11.2 Information on other hazards

Endocrine disrupting properties


Assessment The substance/mixture does not contain components considered to have
endocrine disrupting properties according to REACH Article 57(f) or
Commission Delegated regulation (EU) 2017/2100 or Commission
Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity
Toxicity to fish LC50 (Oncorhynchus mykiss (rainbow trout)) 3.94 mg/l
Exposure time: 96 h
Toxicity to aquatic EC50 (Daphnia magna (Water flea)) 8.8 mg/l
invertebrates Exposure time: 48 h

Chronic toxicity to aquatic NOEC (Daphnia (water flea)): 0.01 mg/l


invertebrates Exposure time: 21 d
The value mentioned relates to the active ingredient tebuconazole.

Toxicity to aquatic plants EC50 (Raphidocelis subcapitata (freshwater green alga)) 9.5 mg/l
Growth rate; Exposure time: 72 h
ErC50 (Skeletonema costatum) 0.03278 mg/l
Exposure time: 72 h
The value mentioned relates to the active ingredient prothioconazole.
SAFETY DATA SHEET

KESTREL 9/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

EC10 (Skeletonema costatum) 0.01427 mg/l


Growth rate; Exposure time: 72 h
The value mentioned relates to the active ingredient prothioconazole.
12.2 Persistence and degradability
Biodegradability Prothioconazole:
Not rapidly biodegradable
Tebuconazole:
Not rapidly biodegradable
Koc Prothioconazole: Koc: 1765
Tebuconazole: Koc: 769
12.3 Bioaccumulative potential
Bioaccumulation Prothioconazole: Bioconcentration factor (BCF) 19
Does not bioaccumulate.
Tebuconazole: Bioconcentration factor (BCF) 35 - 59
Does not bioaccumulate.
12.4 Mobility in soil
Mobility in soil Prothioconazole: Slightly mobile in soils
Tebuconazole: Slightly mobile in soils
12.5 Results of PBT and vPvB assessment
PBT and vPvB assessment Prothioconazole: This substance is not considered to be persistent,
bioaccumulative and toxic (PBT). This substance is not considered to be
very persistent and very bioaccumulative (vPvB).
Tebuconazole: This substance is not considered to be persistent,
bioaccumulative and toxic (PBT). This substance is not considered to be
very persistent and very bioaccumulative (vPvB).
12.6 Endocrine disrupting properties
Assessment The substance/mixture does not contain components considered to have
endocrine disrupting properties according to REACH Article 57(f) or
Commission Delegated regulation (EU) 2017/2100 or Commission
Regulation (EU) 2018/605 at levels of 0.1% or higher.
12.7 Other adverse effects
Additional ecological The ecological data refer to a similar formulation.
information
No other effects to be mentioned.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods

Product Dispose of this product only by using according to the label, or at an


approved landfill or other approved facility.
SAFETY DATA SHEET

KESTREL 10/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

Contaminated packaging Triple rinse containers. Recycle if possible. If allowed under local
authority, burn if circumstances, especially wind direction permit,
otherwise crush and bury in an approved local authority facility. Do not
use container for any other purpose.

SECTION 14: TRANSPORT INFORMATION

This transportation information is not intended to convey all specific regulatory information relat ing to
this product. It does not address regulatory variations due to package size or special trans portat ion
requirements.

ADR/RID/ADN
14.1 UN number 3082
14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(TEBUCONAZOLE, PROTHIOCONAZOLE SOLUTION)
14.3 Transport hazard class(es) 9
14.4 Packaging Group III
14.5 Environm. Hazardous Mark YES
Hazchem Code 3Z

IMDG
14.1 UN number 3082
14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(TEBUCONAZOLE, PROTHIOCONAZOLE SOLUTION)
14.3 Transport hazard class(es) 9
14.4 Packaging Group III
14.5 Marine pollutant YES

IATA
14.1 UN number 3082
14.2 Proper shipping name ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,
N.O.S.
(TEBUCONAZOLE, PROTHIOCONAZOLE SOLUTION )
14.3 Transport hazard class(es) 9
14.4 Packaging Group III
14.5 Environm. Hazardous Mark YES

14.6 Special precautions for user


See sections 6 to 8 of this Safety Data Sheet.

14.7 Transport in bulk according to Annex II of MARPOL and the IBC Code
No transport in bulk according to the IBC Code.

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations/legislation specific for the substance or
mixture
Further information
SAFETY DATA SHEET

KESTREL 11/11
Version 4 / NZ Revision Date: 11.08.2022
102000016447 Print Date: 11.08.2022

HSNO approval-Nr. HSR101293


HSNO Controls See www.epa.govt.nz
ACVM Reg. P9531
ACVM Condition See www.f oodsafety.govt.nz

SECTION 16: OTHER INFORMATION

Abbreviations and acronyms


ADN European Agreement concerning the International Carriage of Dangerous Goods by
Inland Waterways
ADR European Agreement concerning the International Carriage of Dangerous Goods by
Road
ATE Acute toxicity estimate
CAS-Nr. Chemical Abstracts Service number
Conc. Concentration
ECx Ef fective concentration to x %
EINECS European inventory of existing commercial substances
ELINCS European list of notified chemical substances
EN European Standard
EU European Union
IATA International Air Transport Association
IBC International Code for the Construction and Equipment of Ships Carrying Dangerous
Chemicals in Bulk (IBC Code)
ICx Inhibition concentration to x %
IMDG International Maritime Dangerous Goods
LCx Lethal concentration to x %
LDx Lethal dose to x %
LOEC/LOEL Lowest observed effect concentration/level
MARPOL MARPOL: International Convention for the prevention of marine pollution from ships
N.O.S. Not otherwise specified
NOEC/NOEL No observed effect concentration/level
OECD Organization for Economic Co-operation and Development
RID Regulations concerning the International Carriage of Dangerous Goods by Rail
TWA Time weighted average
UN United Nations
WHO World health organisation

The data given here is based on current knowledge and experience. The purpose of this Safety Data
Sheet is to describe products in terms of their safety requirements. The above details do not imply
any guarantee concerning composition, properties or performance of the product.

Reason for Revision: The f ollowing sections have been revised: Section 2: Hazards
Identif ication. Section 3: Composition / Information on Ingredients.
Section 12. Ecological information.
Changes since the last version are highlighted in the margin. This version replaces all previous
versions.

You might also like